Table 3.
Patient characteristics | RP (n = 7) | NRP (n = 29) | p-value |
---|---|---|---|
Median age, years | 70 | 67 | 0.128 |
Median weight (kilograms) | 89.8 | 90 | 0.890 |
Median Gleason score | 7 | 8 | 0.190 |
Median Primary Gleason grade | 4 | 4 | 0.742 |
Analgesic use (%) | 42.8 | 34.5 | 0.690 |
Previous cancer therapy (%) | |||
Antiandrogen | 100 | 93.1 | 1.000 |
Second line anti-hormone agent | 85.7 | 48.2 | 0.104 |
Chemotherapy | 28.6 | 31 | 1.000 |
Docetaxel | 14.2 | 17.2 | 1.000 |
Median serum PSA* (ng/mL) | 20.9 | 5.8 | 0.122 |
RP = rapid progression; NRP = non-rapid progression; PSA = prostate-specific antigen *.